Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.28 Million EUR | -11.32% |
| 2022 | -17.11 Million EUR | -206.61% |
| 2021 | -5.58 Million EUR | 28.56% |
| 2020 | -7.81 Million EUR | 20.22% |
| 2019 | -9.79 Million EUR | 37.39% |
| 2018 | -15.64 Million EUR | 18.47% |
| 2017 | -19.18 Million EUR | 17.17% |
| 2016 | -23.16 Million EUR | -4.47% |
| 2015 | -22.17 Million EUR | -3499.61% |
| 2014 | -616.06 Thousand EUR | 96.01% |
| 2013 | -15.43 Million EUR | -34.06% |
| 2012 | -11.51 Million EUR | 22.92% |
| 2011 | -14.93 Million EUR | -676.21% |
| 2010 | 2.59 Million EUR | 116.75% |
| 2009 | -15.47 Million EUR | 33.26% |
| 2008 | -23.19 Million EUR | -18.54% |
| 2007 | -19.56 Million EUR | -43.45% |
| 2006 | -13.63 Million EUR | -101.9% |
| 2005 | -6.75 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.46 Million EUR | -46.51% |
| 2024 Q2 | -5.46 Million EUR | 0.0% |
| 2023 Q2 | -12.34 Million EUR | -112.94% |
| 2023 Q3 | -3.72 Million EUR | 69.8% |
| 2023 Q4 | -3.72 Million EUR | 0.0% |
| 2023 FY | -19.05 Million EUR | -11.32% |
| 2023 Q1 | -5.79 Million EUR | 35.36% |
| 2022 FY | -17.11 Million EUR | -206.61% |
| 2022 Q2 | -9.83 Million EUR | -119.37% |
| 2022 Q3 | -4.07 Million EUR | 58.56% |
| 2022 Q4 | -8.97 Million EUR | -120.15% |
| 2022 Q1 | -4.48 Million EUR | -111.91% |
| 2021 Q2 | -5.21 Million EUR | -129.25% |
| 2021 Q4 | -2.11 Million EUR | -308.7% |
| 2021 FY | -5.58 Million EUR | 28.56% |
| 2021 Q1 | -2.27 Million EUR | 48.02% |
| 2021 Q3 | -517.49 Thousand EUR | 90.07% |
| 2020 FY | -7.81 Million EUR | 20.22% |
| 2020 Q3 | -1.93 Million EUR | 57.67% |
| 2020 Q4 | -4.37 Million EUR | -126.4% |
| 2020 Q2 | -4.56 Million EUR | -131.09% |
| 2020 Q1 | -1.97 Million EUR | 43.49% |
| 2019 Q3 | -1.42 Million EUR | 81.39% |
| 2019 Q4 | -3.49 Million EUR | -144.49% |
| 2019 Q2 | -7.68 Million EUR | -121.49% |
| 2019 FY | -9.79 Million EUR | 37.39% |
| 2019 Q1 | -3.46 Million EUR | 31.79% |
| 2018 Q1 | -2.73 Million EUR | 30.5% |
| 2018 FY | -15.64 Million EUR | 18.47% |
| 2018 Q4 | -5.08 Million EUR | 0.0% |
| 2018 Q3 | -5.08 Million EUR | -85.63% |
| 2018 Q2 | -2.73 Million EUR | 0.0% |
| 2017 Q4 | -3.94 Million EUR | 0.0% |
| 2017 FY | -19.18 Million EUR | 17.17% |
| 2017 Q1 | -5.65 Million EUR | 5.79% |
| 2017 Q2 | -5.65 Million EUR | 0.0% |
| 2017 Q3 | -3.94 Million EUR | 30.31% |
| 2016 Q3 | -6 Million EUR | -7.52% |
| 2016 FY | -23.16 Million EUR | -4.47% |
| 2016 Q1 | -5.58 Million EUR | -7.7% |
| 2016 Q2 | -5.58 Million EUR | 0.0% |
| 2016 Q4 | -6 Million EUR | 0.0% |
| 2015 Q1 | -5.98 Million EUR | -251.16% |
| 2015 Q2 | -5.98 Million EUR | 0.0% |
| 2015 FY | -22.17 Million EUR | -3499.61% |
| 2015 Q4 | -5.18 Million EUR | 0.0% |
| 2015 Q3 | -5.18 Million EUR | 13.39% |
| 2014 Q1 | -4.26 Million EUR | -8.92% |
| 2014 FY | -616.06 Thousand EUR | 96.01% |
| 2014 Q3 | 3.95 Million EUR | 192.77% |
| 2014 Q2 | -4.26 Million EUR | 0.0% |
| 2014 Q4 | 3.95 Million EUR | 0.0% |
| 2013 FY | -15.43 Million EUR | -34.06% |
| 2013 Q2 | -3.79 Million EUR | 0.0% |
| 2013 Q1 | -3.79 Million EUR | 0.0% |
| 2013 Q3 | -3.91 Million EUR | -3.31% |
| 2013 Q4 | -3.91 Million EUR | 0.0% |
| 2012 FY | -11.51 Million EUR | 22.92% |
| 2011 FY | -14.93 Million EUR | -676.21% |
| 2010 FY | 2.59 Million EUR | 116.75% |
| 2009 FY | -15.47 Million EUR | 33.26% |
| 2008 FY | -23.19 Million EUR | -18.54% |
| 2007 FY | -19.56 Million EUR | -43.45% |
| 2006 FY | -13.63 Million EUR | -101.9% |
| 2005 FY | -6.75 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -494.607% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 84.072% |
| Adocia SA | -17.62 Million EUR | -15.129% |
| Aelis Farma SA | -6.46 Million EUR | -214.007% |
| Biophytis S.A. | -14.33 Million EUR | -41.547% |
| Advicenne S.A. | -6.45 Million EUR | -214.202% |
| genOway Société anonyme | 2.06 Million EUR | 1082.329% |
| IntegraGen SA | -183.77 Thousand EUR | -10939.887% |
| Medesis Pharma S.A. | -4.22 Million EUR | -379.696% |
| Neovacs S.A. | -6.9 Million EUR | -193.708% |
| NFL Biosciences SA | -4.43 Million EUR | -357.925% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -2506.918% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -546.68% |
| Sensorion SA | -22.31 Million EUR | 9.066% |
| Theranexus Société Anonyme | -7.64 Million EUR | -165.422% |
| TME Pharma N.V. | -5.62 Million EUR | -260.74% |
| Valbiotis SA | -7.16 Million EUR | -183.352% |
| TheraVet SA | -2.17 Million EUR | -832.735% |
| argenx SE | -417.15 Million EUR | 95.137% |
| BioSenic S.A. | -7.04 Million EUR | -188.182% |
| Celyad Oncology SA | -8.45 Million EUR | -139.896% |
| DBV Technologies S.A. | -85.24 Million EUR | 76.201% |
| Galapagos NV | -88.26 Million EUR | 77.014% |
| Genfit S.A. | -26.58 Million EUR | 23.672% |
| GeNeuro SA | -14.35 Million EUR | -41.308% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -26.855% |
| Innate Pharma S.A. | -12.66 Million EUR | -60.139% |
| Inventiva S.A. | -102.7 Million EUR | 80.247% |
| MaaT Pharma SA | -19.94 Million EUR | -1.73% |
| MedinCell S.A. | -20.97 Million EUR | 3.285% |
| Nanobiotix S.A. | -26.77 Million EUR | 24.239% |
| Onward Medical N.V. | -35.46 Million EUR | 42.791% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -345.969% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 11.738% |
| Oxurion NV | -12.11 Million EUR | -67.531% |
| Pharming Group N.V. | -4.87 Million EUR | -315.777% |
| Poxel S.A. | -28.76 Million EUR | 29.467% |
| GenSight Biologics S.A. | -29.69 Million EUR | 31.681% |
| Transgene SA | -30.01 Million EUR | 32.4% |
| Financière de Tubize SA | -2.14 Million EUR | -846.28% |
| UCB SA | 604 Million EUR | 103.359% |
| Valneva SE | -82.08 Million EUR | 75.285% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 29.646% |